Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 1Phase 1/2 1

Status

Terminated 5Completed 3Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 1Melanoma 1Glioblastoma 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × infigratinib × Clear all
NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
17 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed
158 enrolled 40 charts
Dermatologic

Melanoma

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Novartis

Phase 2 Completed
26 enrolled 10 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡